Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
LQD
Liquidia CorporationLQDA
$497K+10.2%
Tenet Healthcare logo
Tenet HealthcareTHC
$229M+11.2%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$110K-37.5%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$6K-60.0%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$4.5M+4.5%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's D&A?
Mannkind (MNKD) reported D&A of $6.38M in Q1 2026.
How has Mannkind's D&A changed year-over-year?
Mannkind's D&A increased by 203.0% year-over-year, from $2.11M to $6.38M.
What is the long-term trend for Mannkind's D&A?
Over 3 years (2022 to 2025), Mannkind's D&A has grown at a 54.6% compound annual growth rate (CAGR), from $3.33M to $12.28M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.